Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma

B‐cell activating factor (BAFF) promotes the survival and adhesion of multiple myeloma (MM) cells. Tabalumab (LY2127399) is an anti‐BAFF monoclonal antibody. This phase 1, multicenter, open‐label, nonrandomized, dose‐escalation study evaluated the safety, tolerability, pharmacokinetics, pharmacodyna...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Sci
Autori principali: Iida, Shinsuke, Ogiya, Daisuke, Abe, Yasunobu, Taniwaki, Masafumi, Asou, Hiroya, Maeda, Kaijiro, Uenaka, Kazunori, Nagaoka, Soshi, Ishiki, Tsuyoshi, Conti, Ilaria, Tobinai, Kensei
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2016
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5021044/
https://ncbi.nlm.nih.gov/pubmed/27350068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13000
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi